We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
+13.6%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$479M
AUM Growth
-$87.1M
Cap. Flow
-$83.1M
Cap. Flow %
-17.35%
Top 10 Hldgs %
54.46%
Holding
54
New
9
Increased
12
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$31.3M
2
INCY icon
Incyte
INCY
+$18.2M
3
DFTX
Definium Therapeutics
DFTX
+$17.6M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$15.5M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$14.2M

Top Sells

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$31.4M
2
LLY icon
Eli Lilly
LLY
+$27.9M
3
JNJ icon
Johnson & Johnson
JNJ
+$25M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$23M
5
GILD icon
Gilead Sciences
GILD
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.78B
$47M 9.82%
560,308
-93,264
-14% -$5.4M
BBIO icon
2
BridgeBio Pharma
BBIO
$16.1B
$32.1M 6.7%
+432,014
New +$31.3M
ASND icon
3
Ascendis Pharma A/S
ASND
$16.7B
$29.5M 6.17%
129,111
+9,846
+8% +$2.21M
BMY icon
4
Bristol-Myers Squibb
BMY
$124B
$25.5M 5.33%
420,727
-227,172
-35% -$13.2M
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$2.01B
$24.4M 5.09%
1,043,670
-153,137
-13% -$3.33M
GILD icon
6
Gilead Sciences
GILD
$162B
$22.8M 4.77%
163,905
-125,407
-43% -$17.6M
TERN
7
DELISTED
Terns Pharmaceuticals
TERN
$21.6M 4.5%
409,031
+272,073
+199% +$11.2M
DFTX
8
Definium Therapeutics
DFTX
$5.98B
$19.6M 4.1%
+1,037,984
New +$17.6M
SLNO
9
DELISTED
Soleno Therapeutics
SLNO
$19.3M 4.04%
577,808
+217,468
+60% +$8.53M
BSX icon
10
Boston Scientific
BSX
$64.2B
$18.8M 3.92%
299,318
-61,110
-17% -$4.89M
RARE icon
11
Ultragenyx Pharmaceutical
RARE
$2.82B
$17.8M 3.72%
850,797
+688,247
+423% +$15.5M
INCY icon
12
Incyte
INCY
$23.5B
$17.1M 3.58%
+182,101
New +$18.2M
CYTK icon
13
Cytokinetics
CYTK
$11B
$14.2M 2.97%
215,501
-42,880
-17% -$2.73M
NTRA icon
14
Natera
NTRA
$38.3B
$14.2M 2.96%
70,907
+8,634
+14% +$1.86M
CRVS icon
15
Corvus Pharmaceuticals
CRVS
$1.22B
$13M 2.73%
+891,933
New +$14.2M
GPCR icon
16
Structure Therapeutics
GPCR
$3.51B
$12.3M 2.57%
255,379
+2,478
+1% +$170K
MLYS icon
17
Mineralys Therapeutics
MLYS
$2.43B
$11.9M 2.48%
439,041
+107,192
+32% +$3.14M
EW icon
18
Edwards Lifesciences
EW
$48.7B
$11.6M 2.42%
144,607
-42,441
-23% -$3.5M
MANE
19
Veradermics Inc
MANE
$4.57B
$11M 2.29%
+173,582
New +$8.76M
ADPT icon
20
Adaptive Biotechnologies
ADPT
$3.61B
$10M 2.1%
722,784
-98,411
-12% -$1.57M
HTFL
21
Heartflow Inc
HTFL
$2.19B
$9.82M 2.05%
403,588
+289,731
+254% +$7.87M
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$8.59M 1.79%
+426,551
New +$6.87M
QURE icon
23
uniQure
QURE
$2.76B
$8.03M 1.68%
491,116
+202,771
+70% +$4.11M
IRON icon
24
Disc Medicine
IRON
$2.89B
$7.86M 1.64%
122,978
+12,551
+11% +$871K
SEPN
25
Septerna Inc
SEPN
$1.52B
$7.07M 1.48%
294,360
– –
1
2 3

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
RFWA
RPg Family Wealth Advisory Burlington, Massachusetts $479M AUM 25.83% 1-Year Est. Return
SWM
Silverlake Wealth Management Williston, Vermont $479M AUM 17.75% 1-Year Est. Return
CMI
Clare Market Investments Dallas, Texas $478M AUM
TCM
Towneley Capital Management Laguna Hills, California $478M AUM 16.21% 1-Year Est. Return
LIM
Longfellow Investment Management Boston, Massachusetts $480M AUM 8% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return

Catalio Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Catalio Capital Management held 54 positions worth $479M, down 15% from $566M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Catalio Capital Management withdrew a net $83.1M in Q1 2026, closing 13 positions and reducing 13 holdings. Its most notable exit was BridgeBio Oncology, an estimated $31.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Catalio Capital Management opened a new position in BridgeBio Pharma worth $32.1M.

  • Catalio Capital Management's largest Q1 2026 buy was BridgeBio Pharma: 432,014 shares worth $32.1M.
  • Catalio Capital Management added most to Ultragenyx Pharmaceutical in Q1 2026, an estimated $15.5M increase.
  • Catalio Capital Management's biggest Q1 2026 reduction was Gilead Sciences, cutting an estimated $17.6M.
  • Catalio Capital Management fully exited BridgeBio Oncology in Q1 2026, selling an estimated $31.4M.
  • Catalio Capital Management's ten largest holdings make up 54% of its $479M portfolio in Q1 2026.
  • Catalio Capital Management opened 9 new positions and closed 13 in Q1 2026.
  • Catalio Capital Management's portfolio value fell 15% quarter-over-quarter to $479M.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.